AnaptysBio recently completed a strategic spin-off that separated its biopharma development operations into First Tracks Biotherapeutics, leaving AnaptysBio as a lean royalty management entity. Its primary revenue source stems from royalties tied to GSK’s commercialization of Jemperli, making the company highly dependent on GSK’s execution and market performance. The business model pivots away from R&D towards intellectual property licensing and royalty collection. Key risks include reliance on collaborator success, ongoing litigation, and the inherent uncertainties in patent protection and enforcement. Near-term growth drivers hinge largely on sustained sales momentum of Jemperli and potential milestone payments. The company maintains strong liquidity with no reported debt, positioning it to manage operational expenses and strategic initiatives with a streamlined cost base.